Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fakultní nemocnice Olomouc | UNKNOWN |
| University Hospital Ostrava | OTHER |
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to evaluate the safety and efficacy of medical device Kardi Ai, an ECG telemetry monitoring device in adult population.
The main questions it aims to answer are:
Participants will receive Kardi Ai medical device. They will use it to collect ECG recordings from at least 5 different days and in total collect records of at least 10 hours duration.
The primary objective of the study is to correctly find the given heart rythm disorders using Kardi Ai across all measurements compared to an experienced cardiologist.
The primary objective will be evaluated across all heart rhythm disorders together, using the statistics used in the evaluation of diagnostic tests (sensitivity, specificity, if applicable, positive predictive values and negative predictive values predictive values of the test).
Study procedure:
Familiarisation of the subject with the clinical trial
Signing the informed consent
Handover of the Kardi Ai medical device (packaging hardware components of the Polar H10 chest strap, including instructions for use and QR codes for installation of the Kardi Ai app), registration of the subject in the physician's electronic Case Report Form.
Installation and commissioning of the mobile pohone application by the subject.
Independent measurement of the subject in the home environment. Measurements should be done at least 3 times per week for the duration of at least two hours each.
As part of the ECG recording for the purpose of the clinical trial, measurements will be taken on at least five different days; and the total recording time must be at least 10 hours. If bradycardia is suspected, at least one measurement must be taken overnight for at least 6 hours.
Raw data for each measurement in the Kardi Ai mobile app will be transmitted to the Kardi Ai cloud, where it will be analyzed by AI, including evaluation of the following 7 heart rhythm disorders:
KPIs calculated by AI will be automatically transmitted via API to the EDC system, where the results of each measurement will be stored in a separate form under the specific code of the subject.
Individual ECG recordings will be annotated by the physician. The heart rhythm disorders found in the measurements will be recorded by the physician in the electronic Case Report Form.
Once the data collection is complete, the results obtained by the AI and the results from the physician will be compared by a statistician.
The accuracy and correctness of the ECG interpretation will be evaluated between the Kardi Ai system vs. the physician-based ECG annotation.
Upon completion of the data collection, a questionnaire related to the individual satisfaction with the Kardi Ai system will be completed by each subject of the trial.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group with potential heart rythm disorder | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Medical device | Device | Adding Kardi Ai medical device for detection of heart rythm disorders |
|
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of sensitivity and specificity of Kardi Ai across all measurements and heart rythm disorders. | Evaluation of sensitivity and specificity of Kardi Ai across all measurements and heart rythm disorders. | From enrollment to the end of measurements at 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of sensitivity and specificity of Kardi Ai across all measurements for each monitored heart rythm disorders. | Evaluation of sensitivity and specificity of Kardi Ai across all measurements for each monitored heart rythm disorders. | From enrollment to the end of measurements at 3 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of the quality of ECG measurements | Evaluation of the quality of ECG measurements. ECG will be evaluated by physician annotator, who will adjudicate the quality of the ECG on the three point scale. 1 - excellent(above 90% QRS recognizable), 2- medium(above 70% QRS recognizable), 3 - poor(less than 70% QRS recognizable). | From enrollment to the end of measurements at 3 weeks |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| David Skála | Contact | +420 779 998 100 | david@kardi.ai |
| Name | Affiliation | Role |
|---|---|---|
| Jiří Plášek, doc. MUDr. PhD. FESC | University Hospital Ostrava | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fakultní nemocnice Olomouc | Recruiting | Olomouc | Czechia | 779 00 | Czechia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fakultní nemocnice Ostrava | Recruiting | Ostrava | Czechia | 708 52 | Czechia |
|
| ID | Term |
|---|---|
| D001281 | Atrial Fibrillation |
| D018880 | Atrial Premature Complexes |
| D018879 | Ventricular Premature Complexes |
| D001919 | Bradycardia |
| D013610 | Tachycardia |
| D013617 | Tachycardia, Supraventricular |
| D001145 | Arrhythmias, Cardiac |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005117 | Cardiac Complexes, Premature |
| D000075224 | Cardiac Conduction System Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D004864 | Equipment and Supplies |
Not provided
Not provided
Not provided